SecBot SecBot

DTC Act of 2025

H.R. 3789 Rep. David Taylor (R-OH-2) In committee
  1. Introduced Jun 5
  2. Committee Jun 5
  3. Passed House Next
  4. Passed Senate Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Jun 5, 2025Next: House vote
510d ago Jun 5, 2025: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
1company, 6 filings
Member trades
1trades in the last 90 days
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

1 company
Companies by sector
Consumer & Retail 1
Search all 1 companies, their asks and price moves Subscribe

Summary

Drug-price Transparency for Consumers Act of 2025 or the DTC Act of 2025

Full summary4 paragraphs

This bill requires consumer advertisements for prescription drugs and biological products to include certain price information if the drug or biologic is (1) covered under Medicare or Medicaid, and (2) required to include a risk summary under current law.

Specifically, such advertisements must clearly and conspicuously disclose the wholesale price for a 30-day supply of the drug or biologic and may explain that a consumer may pay a different amount for the drug or biologic depending on the consumer's health insurance coverage.

The requirement does not apply to advertisements for drugs or biologics with a wholesale cost of less than $35 for a one-month supply.

Each violation of this requirement is subject to a civil penalty of not more than $100,000.

Library of Congress summary, Jun 5, 2025

Summary versions
  • Introduced in HouseJun 5, 2025

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 28, 2026.